Construction method and application of plateau qi deficiency and blood stasis syndrome animal model

By using a low-pressure, low-oxygen environment and ice-water bath combined with epinephrine hydrochloride injection, an animal model of high-altitude qi deficiency and blood stasis syndrome, consistent with the clinical syndrome characteristics of traditional Chinese medicine, was constructed. This solved the problems of model reproducibility and incomplete evaluation system in existing technologies, and provided rapid research and treatment basis.

CN119032900AActive Publication Date: 2024-11-29ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411426041.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-12
Publication Date
2024-11-29
Estimated Expiration
2044-10-12

AI Technical Summary

Technical Problem

Existing technologies make it difficult to construct animal models of high-altitude qi deficiency and blood stasis syndrome that are highly reproducible, have a sound evaluation system, and exhibit rapid onset. Furthermore, existing protocols are time-consuming and do not meet the characteristics of rapid onset of high-altitude qi deficiency and blood stasis syndrome.

Method used

A high-altitude environment was simulated by using a low-pressure, low-oxygen environment combined with ice-water baths and epinephrine hydrochloride. Experimental animals were raised in a low-pressure, low-oxygen environment, and ice-water baths and subcutaneous injections of epinephrine hydrochloride were administered at specific time intervals to construct an animal model of high-altitude qi deficiency and blood stasis syndrome.

Benefits of technology

The constructed animal model of high-altitude qi deficiency and blood stasis syndrome is more consistent with the clinical syndrome characteristics of traditional Chinese medicine, providing a scientific basis and an effective tool for the research and treatment of high-altitude qi deficiency and blood stasis syndrome.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032900A_ABST
    Figure CN119032900A_ABST
Patent Text Reader

Abstract

The invention provides a construction method and application of a plateau qi deficiency and blood stasis syndrome animal model, and belongs to the technical field of model animal preparation. The construction method of the plateau qi deficiency and blood stasis syndrome animal model comprises the following steps: feeding an experimental animal in a low-pressure and low-oxygen environment for 1-4 days, and performing ice-water bath every day; and meanwhile, applying epinephrine hydrochloride to the experimental animal for 1-3 times in the 1st-4th day to obtain the plateau qi deficiency and blood stasis syndrome animal model. The method is standard in operation and sound in evaluation system, the constructed plateau qi-deficiency and blood-stasis syndrome animal model better conforms to the characteristics of traditional Chinese medicine clinical syndromes and the characteristics of rapid onset of plateau qi-deficiency and blood-stasis syndromes and the like, the blood-stasis condition of the model is highlighted, and a scientific basis is provided for treating plateau qi-deficiency and blood-stasis syndromes through traditional Chinese medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of model animal preparation, and in particular relates to a method for constructing and applying a plateau qi deficiency and blood stasis syndrome animal model. Background Art

[0002] Plateau Qi deficiency and blood stasis syndrome refers to the fact that due to the thin air in the plateau area, the clear qi source is insufficient, the ancestral qi is deficient, and the lungs cannot breathe and penetrate the heart meridian, resulting in a decline in human body function. In addition, the cold climate characteristics of the plateau easily make the blood appear "thick, sticky, thick, and coagulated" and other manifestations of Qi deficiency and blood stasis syndrome. The main clinical symptoms are shortness of breath, shortness of breath and lazy speech, fatigue, palpitations and chest tightness, insomnia and dreams, chest tightness and heart pain, flank pain, cyanosis of lips and nails, dark purple tongue, and deep and fine pulse. After healthy people enter the plateau from the plain, they will experience chest tightness, shortness of breath, fatigue, shortness of breath or lazy speech to varying degrees. The symptoms are characterized by "getting worse with movement". The incidence and severity of symptoms are positively correlated with the altitude gradient. At present, there are deficiencies in the clinical research on the anti-evidence prescriptions and therapeutic drugs for plateau Qi deficiency and blood stasis syndrome. Therefore, it is very necessary to carry out research on effective preventive and therapeutic drugs for plateau Qi deficiency and blood stasis syndrome. The basis of these studies is to establish an animal model of plateau qi deficiency and blood stasis syndrome with good reproducibility and a sound evaluation system. At present, there are few studies on animal models of plateau qi deficiency and blood stasis syndrome, and the construction operation is not standardized and the evaluation system is not sound. In addition, the existing scheme of constructing a plateau qi deficiency and blood stasis syndrome model through simple low pressure and low oxygen has a long cycle, generally at least 4 weeks, which does not meet the characteristics of the rapid onset of plateau qi deficiency and blood stasis syndrome. Therefore, establishing an animal model of plateau qi deficiency and blood stasis syndrome with good reproducibility, a sound evaluation system and rapid onset is a technical problem that needs to be solved at this stage. Summary of the invention

[0003] In view of this, the purpose of the present invention is to provide a method for constructing and applying an animal model of plateau qi deficiency and blood stasis syndrome. The animal model of plateau qi deficiency and blood stasis syndrome constructed by this method is more in line with the clinical syndrome characteristics, and the operating specifications and evaluation standards are sound, providing a scientific basis for the treatment of plateau qi deficiency and blood stasis syndrome.

[0004] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0005] The invention provides a method for constructing an animal model of plateau qi deficiency and blood stasis syndrome, comprising the following steps: placing an experimental animal in a low-pressure and low-oxygen environment for 1-4 days and carrying out an ice water bath every day; and administering epinephrine hydrochloride to the experimental animal 1-3 times on the 1st to 4th day; the oxygen partial pressure in the low-pressure and low-oxygen environment is 9-12 kPa, the oxygen concentration is 11-20%, and the temperature is 20-25 DEG C.

[0006] Preferably, the experimental animals include rats or mice.

[0007] Preferably, the low-pressure and low-oxygen environment simulates a plateau environment at an altitude of 5500-6500m.

[0008] Preferably, the daily time is from 9:30 am to 10:30 am.

[0009] Preferably, the ice water bath time is 3-6 min.

[0010] Preferably, the method of administering epinephrine hydrochloride includes: administering epinephrine hydrochloride for the first time between 9:30 and 10:30 am on the 1st to 4th day, administering it for the second time after an interval of 1.5-2.5 hours, and performing an ice water bath for 3-6 minutes in between.

[0011] Preferably, the administration is subcutaneous injection.

[0012] Preferably, the constructed plateau qi deficiency syndrome animal model is subjected to systemic behavior status, coagulation function, chrnα1 level in brain, heart and lung tissues and tongue image detection.

[0013] The present invention provides application of the plateau qi deficiency and blood stasis syndrome animal model obtained by the construction method in studying the pathogenesis of plateau qi deficiency and blood stasis syndrome.

[0014] The present invention provides application of the plateau qi deficiency and blood stasis syndrome animal model obtained by the construction method in screening drugs for treating plateau qi deficiency and blood stasis syndrome.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] Based on the TCM syndrome characteristics of plateau acclimatization difficulties, the present invention uses a modeling method of low pressure, hypoxia and drug intervention composite factors to explore the construction of an animal model of plateau qi deficiency and blood stasis syndrome. Through comparative studies, the construction method of the present invention is the best modeling method for obtaining an animal model of plateau qi deficiency and blood stasis syndrome, and operating specifications and evaluation standards are formulated. The plateau qi deficiency and blood stasis syndrome animal model constructed by this method is more in line with the clinical syndrome characteristics of TCM. The model can be used to carry out research on the occurrence mechanism of plateau qi deficiency and blood stasis syndrome, providing a scientific basis for the treatment of plateau qi deficiency and blood stasis syndrome with traditional Chinese medicine. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 The results of the grip test.

[0018] Figure 2 The results of the open field experiment.

[0019] Figure 3 These are the results of four coagulation tests.

[0020] Figure 4 These are the results of chrnα1 content detection in heart, brain and lung tissues.

[0021] Figure 5The statistical results of tongue image detection are shown in Figure 2.

[0022] Figure 6 These are the tongue image detection pictures of mice in each group. DETAILED DESCRIPTION

[0023] The present invention provides a method for constructing an animal model of plateau qi deficiency and blood stasis syndrome, comprising the following steps: placing an experimental animal in a low-pressure and low-oxygen environment for 1-4 days, and performing an ice water bath every day; at the same time, administering epinephrine hydrochloride to the experimental animal 1-3 times on the 1st to 4th day to obtain a plateau qi deficiency syndrome animal model. The oxygen partial pressure in the low-pressure and low-oxygen environment of the present invention is 9-12 kPa, the oxygen concentration is 11-20%, and the temperature is 20-25°C. Based on the TCM syndrome characteristics of plateau acclimatization difficulties, the present invention adopts a modeling method of a composite factor of low pressure, low oxygen and drug intervention to explore the construction of an animal model of plateau qi deficiency and blood stasis syndrome. Compared with the modeling in a low-pressure and low-oxygen environment, the plateau qi deficiency and blood stasis syndrome animal model constructed by the construction method of the present invention is closer to clinical symptoms.

[0024] In the present invention, the adrenaline hydrochloride (Adrenalin hydrochloride, molecular formula: C9H 14 ClNO3, molecular weight: 219.665) is an anti-shock vasoactive drug used for the rescue of cardiac arrest and anaphylactic shock. It can also be used to treat other allergic diseases (such as bronchial asthma and urticaria). It is beneficial for local hemostasis and prolonged drug efficacy when used in combination with local anesthetics.

[0025] In the present invention, the experimental animal includes rats or mice, preferably mice. The mice of the present invention are preferably 8-10 weeks old and 18-20g.

[0026] In the present invention, the low-pressure and low-oxygen environment simulates the plateau environment at an altitude of 5500-6500m. The low-pressure and low-oxygen environment of the present invention is implemented in a low-pressure and low-oxygen chamber, and the actual oxygen pressure in the low-pressure and low-oxygen chamber is preferably 9-11 kPa, the actual oxygen concentration is preferably 11-16%, and the temperature is preferably 21-24°C.

[0027] In the present invention, the ice water bath time is 3-6 minutes. In the present invention, the experimental animals are subjected to ice water bath treatment at 9:30 to 10:30 every morning under a low-pressure and low-oxygen environment. The ice water bath treatment time of the present invention is preferably 10:00 every morning.

[0028] In the present invention, the method of administering epinephrine hydrochloride includes: injecting the experimental animal with epinephrine hydrochloride for the first time at 9:30 to 10:30 a.m. on the 1st to 4th day after low-pressure and low-oxygen treatment, injecting the animal subcutaneously for the second time after an interval of 1.5 to 2.5 hours, and performing an ice water bath for 3 to 6 minutes in between. The method of injecting epinephrine hydrochloride in the present invention preferably includes: injecting the experimental animal with epinephrine hydrochloride for the first time at 10 a.m. on the 3rd day after low-pressure and low-oxygen treatment, injecting the animal subcutaneously for the second time after an interval of 2 hours, and performing an ice water bath for 3 to 6 minutes in between.

[0029] In the present invention, the constructed animal model of plateau qi deficiency and blood stasis syndrome is subjected to systemic behavior, coagulation function, human nicotinic cholinergic receptor α1 (chrnα1) level in brain, heart and lung tissues and tongue image detection. The systemic behavior described in the present invention is detected by gripping force detection and open field test. The gripping force test described in the present invention can reflect the "qi deficiency" of animals with plateau qi deficiency and blood stasis syndrome; the open field test (OFT) is mainly used to study the motor ability and anxiety-like behavior of mice, and the gripping force test can be used as an indicator to reflect the degree of "qi deficiency". The coagulation function described in the present invention can reflect the "blood stasis" of the syndrome model. The chrnα1 level in brain, heart and lung tissues described in the present invention can reflect the "qi deficiency" of animals with plateau qi deficiency and blood stasis syndrome; tongue image detection, as a characteristic indicator of traditional Chinese medicine, can reflect the typical "dark purple tongue" phenomenon of qi deficiency and blood stasis.

[0030] The present invention also provides the application of the plateau qi deficiency and blood stasis syndrome animal model obtained by the construction method in screening drugs for treating plateau qi deficiency and blood stasis syndrome or studying the pathogenesis of plateau qi deficiency and blood stasis syndrome.

[0031] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0032] Example 1

[0033] The experimental animals of this example were prepared as follows:

[0034] SPF male C57BL / 6J mice, 8-10 weeks old, weighing 18-20 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. The mouse basal feed was provided by Beijing Weitonglihua Experimental Animal Technology Co., Ltd.

[0035] The breeding environment temperature was 23-25°C, the humidity was (45±10)%, the laboratory was kept quiet and ventilated, and the experimental animals were kept in animal cages under 12h light / dark conditions. According to the standard breeding conditions for mice, they were adaptively fed for 7 days before the start of the experiment and the cages were cleaned once a day to keep them clean.

[0036] The method for constructing an animal model of plateau qi deficiency and blood stasis syndrome is as follows:

[0037] The prepared mice were placed in a low-pressure hypoxic chamber and raised to a simulated plateau environment of 6000m at an altitude of 20m / s. The actual oxygen pressure in the low-pressure hypoxic chamber was 9.5-9.7kPa, and the oxygen concentration was 11-20%, and the treatment was 3d. During the period, ice water baths were performed for 3-6min at 10:00 am on the 1st and 2nd days, and then returned to the low-pressure hypoxic chamber; at 10:00 am on the 3rd day, the mice were subcutaneously injected with 0.65mg / kg of epinephrine hydrochloride for the first time (purchased from Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., item number: H44020575), and after an interval of 2h, the second subcutaneous injection of epinephrine hydrochloride was performed at 0.65mg / kg, and an ice water bath was performed for 3-6min in the middle, and then the mice that had completed the above operation were returned to the low-pressure hypoxic chamber. The overall treatment time of this construction method is a complete 3d, that is, the modeling is completed.

[0038] Example 2

[0039] The experimental animals were prepared as in Example 1.

[0040] The method for constructing an animal model of plateau qi deficiency and blood stasis syndrome is as follows:

[0041] The prepared mice were placed in a low-pressure hypoxic chamber, and raised to a simulated plateau environment of 5500m at an altitude of 20m / s for 2 days. An ice water bath was performed at 9:30 am on the first day for 3-6 minutes; at 9:30 am on the second day, the mice were subcutaneously injected with 0.55mg / kg of epinephrine hydrochloride for the first time, and after an interval of 1.5h, the second subcutaneous injection of 0.55mg / kg of epinephrine hydrochloride was performed, with an ice water bath for 3-6 minutes in between, and then the mice that had completed the above operations were placed back in the low-pressure hypoxic chamber. The overall processing time of this construction method is a full 2 ​​days, that is, the modeling is completed.

[0042] Example 3

[0043] The experimental animals were prepared as in Example 1.

[0044] The method for constructing an animal model of plateau qi deficiency and blood stasis syndrome is as follows:

[0045] The prepared mice were placed in a low-pressure hypoxic chamber, and raised to a simulated plateau environment of 6500m at an altitude of 20m / s for 4 days. Ice water baths were performed for 3-6 minutes at 10:30 am every day on the 1st to 3rd days; at 10:30 am on the 4th day, the mice were subcutaneously injected with 0.75mg / kg of epinephrine hydrochloride for the first time, and 2.5h later, the second subcutaneous injection of 0.75mg / kg of epinephrine hydrochloride was performed, with an ice water bath for 3-6 minutes in between, and then the mice that had completed the above operations were placed back in the low-pressure hypoxic chamber. The overall processing time of this construction method is a complete 2d, that is, the modeling is completed.

[0046] Comparative Example 1

[0047] The experimental animals were prepared as in Example 1.

[0048] The method for constructing an animal model of plateau qi deficiency and blood stasis syndrome is as follows:

[0049] The prepared mice were placed in a low-pressure hypoxic chamber and raised to a simulated plateau environment of 6000m at an altitude at a speed of 20m / s for 3 days. At the same time, 80mg / kg of cyclophosphamide was injected intraperitoneally once at 10 am every day, and the mice were returned to the low-pressure hypoxic chamber after treatment. The overall treatment time of this construction method was a full 3 days, that is, the model was completed.

[0050] Comparative Example 2

[0051] The experimental animals were prepared as in Example 1.

[0052] The method for constructing an animal model of plateau qi deficiency and blood stasis syndrome is as follows:

[0053] The prepared mice were placed in a low-pressure hypoxic chamber and raised to a simulated plateau environment of 6000m at an altitude of 20m / s for 3 days. At the same time, at 10:00 am on the 3rd day, the mice were subcutaneously injected with 0.65mg / kg of epinephrine hydrochloride for the first time, and 2 hours later, the second subcutaneous injection of epinephrine hydrochloride was given at 0.65mg / kg, and then the mice that had completed the above operations were placed back in the low-pressure hypoxic chamber. The overall treatment time of this construction method was a full 3 days, that is, the model was completed.

[0054] Experimental Example 1

[0055] 1. Grouping

[0056] Eight SPF male C57BL / 6J mice (8-10 weeks old, 18-20 g) purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. were raised in the normal way without any treatment and served as the normal group.

[0057] Eight plateau Qi deficiency and blood stasis animal models constructed in Comparative Example 1 were taken as the cyclophosphamide group.

[0058] Eight plateau Qi deficiency and blood stasis animal models constructed in Comparative Example 2 were taken as the adrenaline group.

[0059] Eight plateau Qi deficiency and blood stasis animal models constructed in Example 1 were taken as the adrenaline + ice bath group.

[0060] 2. Detection of indicators of each group of mice

[0061] The mice in the above groups were subjected to grasping strength test, open field test, four coagulation tests, chrnα1 content in heart, brain and lung tissues and tongue image test.

[0062] The gripping force detection steps are as follows: using the YLS-13A rat and mouse gripping force tester, placing the mice on the gripping force test sensing mesh plate, and then dragging them to measure the gripping force of each group of experimental animals.

[0063] The steps of the open field experiment are as follows: an open field test box is used, which is evenly divided into 4 boxes with equal bottom areas. The size of each box is 50cm×50cm×40cm. The outer peripheral wall of the box is black. The area of ​​the bottom area near the wall constitutes the peripheral activity area, and the area of ​​the remaining area constitutes the central activity area. Before the test, the mice are placed in the open field test box to adapt for 15 seconds. At the beginning of the experiment, the mice are placed in the center of the open field. When the operator completes the action of releasing the mouse, the camera directly above the test box begins to track and record synchronously, and the recording time is 5 minutes. The evaluation indicators of this open field experiment are the total distance of the mouse's activities (peripheral area + central area), the distance of the central area's activities, and the time spent in the central area.

[0064] The steps of the four coagulation tests are as follows: Before the test, whole blood containing anticoagulants is subjected to 3000 r / min -1 , centrifuged for 15 minutes to obtain plasma, and then the prothrombin time (prothrombin time, PT), activated partial thromboplastin time (ac-tivated partial thromboplastin time, APTT), thrombin time (thrombin time, TT) and fibrinogen (fibrinogen, FIB) content were tested according to the coagulometer operating procedures.

[0065] Detection of chrnα1 levels in brain, heart, and lung tissues: All groups of mice were tested using ELISA kits according to the instructions. ELISA kits were provided by Jiangsu ELISA Co., Ltd. (Nanjing, China). Optical density was measured at a wavelength of 450 nm using a microplate reader (MULTISKANEX, Thermoscientific). The levels of chrnα1 in brain, heart, and lung tissues were calculated based on the standard curve.

[0066] The steps for tongue image detection are as follows: Before sampling, place the mouse anesthetized with isoflurane on A4 white paper or a dedicated macro photography table for digital photography. Use image J to analyze the RGB values ​​of the tongue surface and tongue base.

[0067] 3. Results Analysis

[0068] The grip test results are as follows: Figure 1 As shown, compared with the normal group, the grip strength of the cyclophosphamide group, the adrenal group, and the adrenaline + ice bath group showed a downward trend, which was statistically significant.

[0069] The results of the open field test are as follows Figure 2As shown in the figure, compared with the normal group, the central zone distance, number of entries and total distance in the cyclophosphamide group, the adrenal group and the adrenaline + ice bath group showed a downward trend, but the central zone distance and number of entries in the adrenaline + ice bath group were more significant (P < 0.001).

[0070] The results of the four coagulation tests are as follows Figure 3 As shown in the figure, compared with the normal group, the FIB levels in the epinephrine group and the epinephrine + ice bath group were significantly increased (P < 0.05), while there was no increasing trend in the cyclophosphamide group.

[0071] The experimental results of chrnα1 content in heart, brain and lung tissues are as follows Figure 4 As shown, compared with the normal group, the grip strength of the model group showed a downward trend, which was statistically significant; the chrnα1 content in the heart, brain, and lung tissues of the adrenaline group and the adrenaline + ice bath group showed an upward trend.

[0072] Tongue test results Figure 5-Figure 6 As shown in the figure, compared with the normal group, the tongue color of the model group was dull, and the RGB values ​​of the tongue bottom were analyzed by image J, and the RGB values ​​of the tongue bottom showed a downward trend.

[0073] The overall statistical results of the above results are shown in Table 1, indicating that the model mice in the adrenaline + ice bath group had statistical significance in the main symptoms, concomitant symptoms and TCM characteristic indicators, indicating that the plateau Qi deficiency and blood stasis syndrome animal model obtained by the construction method of the present invention is more in line with the characteristics of plateau Qi deficiency and blood stasis syndrome and the clinical syndrome characteristics of TCM.

[0074] Table 1 Results of evaluation index responses of mice in each group

[0075]

[0076] Note: "√" means that the model is statistically significant in this indicator in line with the expected results of the plateau qi deficiency and blood stasis syndrome model, and "×" means there is no statistical significance.

[0077] In summary, the experimental results show that by modeling mice for 3 days and subcutaneously injecting epinephrine hydrochloride on the third day of modeling, it was found that compared with the normal group and other model groups, the total distance, distance and number of times that mice in the low-pressure and low-oxygen combined epinephrine plus ice bath group entered the central area were significantly reduced, and the four coagulation FIBs were significantly increased, indicating that the animal model of plateau qi deficiency and blood stasis syndrome obtained by the construction method of the present invention is more in line with the clinical syndrome characteristics of traditional Chinese medicine, and provides a scientific basis for the treatment of plateau qi deficiency and blood stasis syndrome with traditional Chinese medicine.

[0078] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for constructing an animal model of plateau qi deficiency and blood stasis syndrome, characterized in that: The steps include: The experimental animals were placed in a low-pressure and low-oxygen environment for 1-4 days and given an ice-water bath every day; at the same time, adrenaline hydrochloride was administered to the experimental animals 1-3 times on the 1st to 4th day; The oxygen partial pressure in the low-pressure and low-oxygen environment is 9-12 kPa, the oxygen concentration is 11-20%, and the temperature is 20-25°C.

2. The construction method according to claim 1, characterized in that: The experimental animals include rats or mice.

3. The construction method according to claim 1, characterized in that: The low-pressure and low-oxygen environment simulates a plateau environment at an altitude of 5500-6500m.

4. The construction method according to claim 1, characterized in that: The time each day is from 9:30 am to 10:30 am.

5. The construction method according to claim 1, characterized in that: The ice water bath time is 3-6 min.

6. The construction method according to claim 1, characterized in that: The method of administering epinephrine hydrochloride includes: administering epinephrine hydrochloride for the first time between 9:30 and 10:30 am on the 1st to 4th day, administering it for the second time after an interval of 1.5 to 2.5 hours, and performing an ice water bath for 3 to 6 minutes in between.

7. The construction method according to claim 6, characterized in that: The administration is subcutaneous injection.

8. The construction method according to claim 1, characterized in that: The constructed animal model of plateau qi deficiency syndrome was tested for systemic behavior, coagulation function, chrnα1 levels in brain, heart and lung tissues, and tongue appearance.

9. Use of the plateau qi deficiency and blood stasis syndrome animal model obtained by the construction method according to any one of claims 1 to 8 in studying the pathogenesis of plateau qi deficiency and blood stasis syndrome.

10. Use of the plateau qi deficiency and blood stasis syndrome animal model obtained by the construction method according to any one of claims 1 to 8 in screening drugs for treating plateau qi deficiency and blood stasis syndrome.

Citation Information

Patent Citations

  • Method for establishing acute high altitude anoxia and anxiety stress response animal model

    CN106035210A

  • Method for establishing hypertensive-emergency animal model

    CN107466953A

  • Building method of blood stasis and phlegm coagulation syndrome and laryncarcinoma syndrome combined animal model

    CN110432225A

  • Method for establishing acute plateau hypobaric and hypoxic lung injury mouse model

    CN113907041A